Ahead of the Bell: inVentiv confirms sales talks

NEW YORK

Shares of inVentiv Health Inc. continued their climb in Monday premarket trading after the company confirmed that it has been approached by a potential buyer.

Shares of inVentiv, which provides services for the pharmaceutical and life sciences industries, had surged in Friday trading on reports the company was considering a sale. Later that day, inVentiv said financial investors had approached the company about a potential sale, and confirmed that it has retained Goldman Sachs as an adviser.

The Somerset, N.J., company said it does not plan to comment any further on the sales talks unless it agrees to be acquired.

Shares of inVentiv Health rose $1.74, or 8.7 percent, to $21.80 in premarket trading. On Friday they jumped 17 percent and closed at $20.06, touching an annual high of $21.19 during the day.